{"nctId":"NCT00350636","briefTitle":"A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo","startDateStruct":{"date":"2006-06"},"conditions":["Overactive Bladder"],"count":789,"armGroups":[{"label":"Oxybutynin topical gel","type":"EXPERIMENTAL","interventionNames":["Drug: Oxybutynin topical gel"]},{"label":"Placebo topical gel","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo topical gel"]}],"interventions":[{"name":"Oxybutynin topical gel","otherNames":["Oxybutynin"]},{"name":"Placebo topical gel","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females and males, 18 years of older with overactive bladder symptoms\n\nExclusion Criteria:\n\n* Treatable conditions that may cause urinary incontinence\n* Medical conditions in which it would be unsafe to use an anti-cholinergic agent.\n* The use of concomitant drugs that would confound the efficacy evaluation.\n* The use of concomitant drugs that would be unsafe with an anti-cholinergic agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Baseline Average Number of Daily Incontinence Episodes","description":"Average number of daily incontinence episodes at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"3.26"},{"groupId":"OG001","value":"5.4","spread":"3.28"}]}]}]},{"type":"SECONDARY","title":"Baseline Average Daily Urinary Frequency","description":"Number of daily urinary voids","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"3.34"},{"groupId":"OG001","value":"12.2","spread":"3.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Daily Urinary Frequency","description":"Change from baseline in average daily urinary frequency","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"3.21"},{"groupId":"OG001","value":"-2.0","spread":"2.82"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Average Daily Number of Incontinence Episodes","description":"Change from Baseline to Week 12 in average daily number of incontinence episodes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"2.73"},{"groupId":"OG001","value":"-2.5","spread":"3.06"}]}]}]},{"type":"SECONDARY","title":"Baseline Average Urine Void Volume","description":"Baseline average urine void volume","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.4","spread":"65.85"},{"groupId":"OG001","value":"167.9","spread":"68.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Urine Void Volume","description":"Change from baseline to Week 12 in average urine void volume","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":"65.33"},{"groupId":"OG001","value":"3.8","spread":"53.79"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":389},"commonTop":["Urinary tract infection","Headache","Upper respiratory tract infection","Dry mouth","Sinusitis"]}}}